ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO466

Non-Proteinuric versus Proteinuric Phenotypes in Diabetic Nephropathy: A Propensity Score Matched Analysis of a Nationwide, Biopsy-Based Cohort Study

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Yamanouchi, Masayuki, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Furuichi, Kengo, Kanazawa University, Kanazawa, Japan
  • Hoshino, Junichi, Toranomon Hospital, Tokyo, Japan
  • Ubara, Yoshifumi, Toranomon Hospital, Tokyo, Japan
  • Wada, Takashi, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan

Several cross-sectional studies have recently shown that a proportion of patients with type 2 diabetes mellitus develop loss of renal function without overt proteinuria or even without microalbuminuria, suggesting the existence of non-proteinuric phenotype of diabetic nephropathy. Their clinicopathological characteristics and renal prognosis, however, are scarce.


We retrospectively assessed patients with type 2 diabetes mellitus, who underwent clinical renal biopsy from Jan 1, 1985 to Dec 31, 2016 and had follow-up data until Dec 31, 2017, from the Japan’s nationwide multicenter renal biopsy registry. Among 795 patients, we restricted 526 patients with reduced renal function (defined as estimated glomerular filtration rate <60 mL/min/1.73m2) and had a pathological diagnosis of diabetic nephropathy as the only glomerular disease diagnosis. 88 were non-proteinurics (urine albumin to creatinine ratio (UACR) <300 mg/gCre), and 438 patients were proteinurics (UACR ≥300 mg/gCre). For comparative analyses, we derived one-to-one paired cohorts of those without proteinuria versus those with proteinuria using propensity-score matching (matched by age, gender, and baseline eGFR). The primary endpoint was progression of CKD defined as new-onset ESRD, decrease of eGFR by ≥ 50%, or doubling of serum creatinine.


In the matched analyses (82 patients in each group), patients with non-proteinuric diabetic nephropathy had lower systolic blood pressure and total cholesterol level, higher serum albumin level, and less frequent typical pathological lesions. After a median follow-up of 3.0 years (IQR 1.0-6.6) from the date of renal biopsy, 65 (40%) of the 164 matched patients had renal events. The 5-year CKD progression-free survival for all patients was 63.3% (95% CI, 53.3-71.7): 86.7% (95% CI, 72.5-93.8) for the non-proteinuric diabetic nephropathygroup and 43.2% (95% CI, 30.2-55.6) for the proteinuric diabetic nephropathygroup (log-rank test p<0.001). The lower renal risk in non-proteinuric diabetic nephropathy group was consistent across all subgroup analysis.


Patients with non-proteinuric diabetic nephropathy had lower blood pressure and less typical morphological changes, and were at lower risk of CKD progression.